Friday, March 6, 2026

BC Partners and Bpifrance complete acquisition of Biogaran

BC Partners and France’s public investment bank Bpifrance have confirmed they have completed the acquisition of Biogaran from Servier. Biogaran is one of the major generic medicines players in France.

The transaction closed after the information and consultation process with Biogaran’s Social and Economic Committee (CSE) and following receipt of the required regulatory approvals. These included European clearances and authorisation under France’s foreign investment control regime (FDI screening).

Commitments linked to France

According to the acquirers, Biogaran is expected to continue operating under its existing business model and to maintain its role within the French healthcare system. BC Partners said it made commitments to French authorities, including keeping the company’s headquarters and operations in France, safeguarding jobs, maintaining its subcontracting model, and ensuring industrial, logistical and commercial continuity for patients and partners.

Bpifrance is joining as a significant minority shareholder and will have board representation, which the parties describe as reinforcing Biogaran’s long-term anchoring in France.

Leadership appointment

Following completion of the deal, Erick Roche is set to be appointed Chief Executive Officer of Biogaran, effective by the end of March 2026. Roche previously led Biogaran as CEO for 15 years.

Strategic priorities

BC Partners said it plans to build on Biogaran’s position in generics and support expansion into biosimilars and consumer healthcare products. Biogaran was founded in 1996 and, according to the company, offers more than 1,070 medicines and services. Its statutory net turnover is €1.122 billion, and it sold 357 million boxes of medicines in France over the last 12 months.

The information was disclosed by BC Partners in connection with the completion of the acquisition.